Skip to main content
Premium Trial:

Request an Annual Quote

Ligon Discovery Nets $1M Investment

NEW YORK (GenomeWeb News) – Ligon Discovery, a protein microarray developer based in Cambridge, Mass., has reeled in $1 million in financing from IncTank Ventures, Ligon Discovery Co-founder Patrick Kleyn confirmed today.

The firm plans to use the venture funding to screen more than 100 proteins that could be used for drugs.

Ligon's small-molecule microarrays (SMMs) technology platform was developed by and licensed from Harvard University and Broad Institute.

SMMs use surface chemistry technology to attach unmodified chemical collections to a solid surface, enabling massively-parallel screening against protein targets of any function, according to the firm's website.

The technology enables researchers to screen entire protein families, molecular pathways, and genome-wide targets in parallel to identify small molecules with optimal characteristics for drug development.

The company also confirmed that IncTank General Partner Christian Bailey has joined Ligon's board of directors.

The Scan

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.

Researchers Retrace Key Mutations in Reassorted H1N1 Swine Flu Virus With Avian-Like Features

Mutations in the acidic polymerase-coding gene boost the pathogenicity and transmissibility of Eurasian avian-like H1N1 swine influenza viruses, a PNAS paper finds.

Genome Sequences Reveal Evolutionary History of South America's Canids

An analysis in PNAS of South American canid species' genomes offers a look at their evolutionary history, as well as their relationships and adaptations.

Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA

In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels.